The FDA document was updated May 14, 2026 to reflect the reversal and to flag that the agency will consult the Pharmacy Compounding Advisory Committee, or PCAC, before the end of February 2027 about whether GHK-Cu should be added to the permanent 503A bulks list
Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S , Overman MJ
Daver NG, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour E, Hendrickson S, Brandt M, Pierce S, Gordon T, Pemmaraju N, Andreeff M , Ning J, Kornblau S, Kadia TM, Dinardo CD, Konopleva M, Allison JP, Kantarjian HM, Sharma P
Nov 2014;140 Suppl(Suppl 1):S91-7